Filament Health, a subsidiary of Rhelion Life Sciences, has completed another delivery of its patented psilocybin drug candidate PEX010 to Germany's Central Institute of Mental Health. This supports Germany's pioneering compassionate use program for psilocybin in treatment-resistant depression, the first of its kind in the EU. The delivery demonstrates Filament's capability to manufacture and supply pharmaceutical-grade psilocybin internationally, positioning the company to participate in emerging regulated markets as legal access expands globally. Rhelion plans to leverage Filament's manufacturing, regulatory, and supply expertise to pursue future commercial opportunities as psychedelic medicine access grows worldwide.
Marshall Tucker, CFO of Smucker, sold 18,482 shares of the company, generating $2.4 million from the sale. This insider transaction may indicate personal financial planning or a shift in confidence, which investors often watch closely. The sale's imp...
Deutsche Bank upgraded Dunelm Group PLC to a 'buy' rating, expecting accelerated earnings growth driven by a new strategy presentation. The retailer plans to enhance its digital offerings and increase store investments to capture a larger market shar...
Broadcom projects its AI semiconductor revenue will jump from $58 billion in fiscal 2026 to about $230 billion by fiscal 2028, signaling rapid growth in AI infrastructure demand. In Q3, AI-related revenue surged 221% to $16.7 billion, with a strong o...
Hargreaves Lansdown, the UK's largest retail investment platform, plans to offer physically backed Bitcoin and Ethereum exchange-traded notes (ETNs) following the Financial Conduct Authority's lifting of a four-year ban on retail crypto ETNs. Despite...
Kroger announced a $1.65 billion acquisition of Giant Eagle, pending regulatory approval and expected to close in 2027. This deal comes while Kroger is still embroiled in litigation with Albertsons over a failed $24.6 billion merger, centered on disp...
